Topic: Myocardia

A producer and former employee of Myocardia reported that the company was acquired by Bristol Myers Squibb. The employee, who managed clinical trials, expressed skepticism about the acquisition and was subsequently fired for refusing the COVID-19 vaccine. Myocardia produces treatments for heart conditions, leading to speculation about the pharmaceutical industry's interest in myocarditis remedies.

Media outlets are reporting on "Post-Pandemic Stress Disorder" as a cause for sudden heart conditions in young adults, which is viewed as a way to deflect from vaccine side effects. Simultaneously, Bristol Myers Squibb and Pfizer are running heavy ad rotations for blood clot and heart disease medications. Notably, Bristol Myers Squibb recently completed a $13 billion acquisition of MyoKardia, a company specializing in heart disease treatments.